Open AccessDiskussionnye voprosy vedeniya zhenshchin s antifosfolipidnymi antitelami pri primenenii VRT
Author(s) -
Marina Ivanovna Mirashvili,
Мирашвили Марина Ивановна,
М. С. Зайнулина,
Зайнулина Марина Сабировна,
С. А. Сельков,
Сельков Сергей Алексеевич,
Alexander M. Gzgzyan,
Гзгзян Александр Мкртичевич
Publication year - 2013
Publication title -
žurnalʺ akušerstva i ženskihʺ boleznej
Language(s) - English
Resource type - Journals
eISSN - 1684-0461
pISSN - 1683-9366
DOI - 10.17816/jowd62326-33
Subject(s) - medicine , plasmapheresis , intravenous immunoglobulin therapy , antiphospholipid syndrome , pregnancy , antibody , gynecology , obstetrics , aspirin , intravenous immunoglobulins , live birth , immunology , genetics , biology
There are many controversies in the management antiphospholipid antibodies-positive women undergoing assisted reproductive technologies. Controversial and important is not only the effect of antiphospholipid antibodies (APA) on the success of IVF, but also approaches to the management of this group of women. The aim of this work was to study the prevalence of antiphospholipid antibodies in women with 3 or more IVF failures and effectiveness of IVF in women with APA treatment with membrane plasmapheresis before IVF and intravenous immunoglobulin during IVF. In women with 3 or more IVF implantation failure APA were detected in 35.95 % of cases. The use of intravenous immunoglobulin along with the standard therapy is a safe and effective for improvement of IVF outcomes in women with antiphospholipid syndrome (APS) or the presence of APA. The most effective is a combination of the membrane plasmapheresis therapy before IVF and intravenous immunoglobulin during IVF standard therapy including LMWH and low-dose aspirin in IVF protocol. This therapy in patients with the presence of APA increases the pregnancy rate after IVF to 46.15 %.